Publicaciones en las que colabora con José Luis Lanciego Pérez (13)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome

    Journal of Molecular Medicine, Vol. 101, Núm. 12, pp. 1587-1601

2022

  1. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

2011

  1. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Production of highly pure human glycosylated GDNF in a mammalian cell line

    International Journal of Pharmaceutics, Vol. 385, Núm. 1-2, pp. 6-11

2009

  1. Effective GDNF brain delivery using microspheres-A promising strategy for Parkinson's disease

    Journal of Controlled Release, Vol. 135, Núm. 2, pp. 119-126

2008

  1. Controlled drug delivery to the brain: an overview

    Handbook of particulate drug delivery (American Scientific Publishers), pp. 121 - 142

  2. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 69, Núm. 3, pp. 844-851

2007

  1. Microencapsulación de factores neurotróficos: Aplicación al tratamiento de la enfermedad de Parkinson

    Mapfre Medicina, Vol. 18, Núm. 4, pp. 240-248

  2. Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor

    International Journal of Pharmaceutics, Vol. 344, Núm. 1-2, pp. 9-15

2006

  1. Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson

    Anales del sistema sanitario de Navarra, Vol. 29, Núm. 3, pp. 325-335